Edition:
United Kingdom

Axsome Therapeutics Inc (AXSM.OQ)

AXSM.OQ on NASDAQ Stock Exchange Global Market

4.75USD
12 Dec 2017
Change (% chg)

$-0.20 (-4.04%)
Prev Close
$4.95
Open
$4.95
Day's High
$4.95
Day's Low
$4.75
Volume
17,536
Avg. Vol
21,747
52-wk High
$7.20
52-wk Low
$3.55

Chart for

About

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02... (more)

Overall

Beta: --
Market Cap(Mil.): $146.39
Shares Outstanding(Mil.): 23.61
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Sabby Management Reports A 5.52 Percent Passive Stake In Axsome Therapeutics

* SABBY MANAGEMENT, LLC REPORTS A 5.52 PERCENT PASSIVE STAKE IN AXSOME THERAPEUTICS INC AS OF DEC 1 - SEC FILING Source text : [http://bit.ly/2jNkBHB] Further company coverage:

04 Dec 2017

BRIEF-Axsome Therapeutics Announces AXS-07 For The Treatment Of Migraine

* AXSOME THERAPEUTICS ANNOUNCES AXS-07 FOR THE TREATMENT OF MIGRAINE

28 Nov 2017

BRIEF-Axsome Therapeutics reports Q3 loss per share $0.27

* Axsome Therapeutics reports third quarter 2017 financial results

08 Nov 2017

BRIEF-Axsome enters agreement to sell up to $30 mln of shares of co's common stock

* Axsome Therapeutics-entered sales agreement to sell through leerink up to $30 million of shares of co's common stock,par value $0.0001/share-SEC filing Source text : (http://bit.ly/2gxqvzm) Further company coverage:

20 Oct 2017

BRIEF-Axsome Therapeutics reports Q2 loss per share $0.30

* Axsome Therapeutics reports second quarter 2017 financial results

09 Aug 2017

BRIEF-Axsome Therapeutics announces AXS-06 meets primary endpoint in phase 1 clinical trial

* Axsome Therapeutics announces AXS-06 (moseic meloxicam and esomeprazole) meets primary endpoint in phase 1 clinical trial

25 Jul 2017

BRIEF-Axsome Therapeutics initiates Phase 2/3 trial of AXS-05 for Alzheimer’s disease agitation

* Axsome Therapeutics initiates Phase 2/3 trial of AXS-05 for Alzheimer’s disease agitation Source text for Eikon: Further company coverage:

17 Jul 2017

BRIEF-Axsome appoints John Golubieski as CFO

* Axsome Therapeutics appoints John Golubieski as chief financial officer

06 Jul 2017

Earnings vs. Estimates